Literature DB >> 9579152

Does a single plasma phenylalanine predict quality of control in phenylketonuria?

A MacDonald1, G W Rylance, D Asplin, S K Hall, I W Booth.   

Abstract

A 1993 MRC working group on phenylketonuria suggested standardising blood phenylalanine measurements by taking blood samples at the same time each day. Since it is not known how representative of a 24 hour period a single phenylalanine concentration is, the aim of this study was to investigate the 24 hour variability of plasma phenylalanine in well controlled children with phenylketonuria. Sixteen subjects, 12 girls and four boys aged 1 to 18 years, had hourly venous blood samples collected for 13 hours between 09.00 and 21.00 on one day. Serial skin puncture blood specimens were then collected at 24.00, 03.00, and 06.00 within the same 24 hour period. All food and drink was weighed. The median variation in plasma phenylalanine concentration was 155 mumol/l/day, with a minimum of 80 and a maximum of 280. The highest concentration occurred in the morning between 6.00 and 9.00 in 63% of subjects; the lowest occurred between midday and midnight in 94%. Concentrations < 100 mumol/l occurred in 46% of children below 11 years, three having concentrations < 30 mumol/l for two, six, and seven hours respectively. Three of five subjects had concentrations above the MRC guidelines for 24% of the period studied. Except in two subjects, the blood concentrations did not rise in response to phenylalanine consumption. However, the greater the quantity of protein substitute taken between waking and the 16.00 specimen, the larger the decrease in daytime phenylalanine concentration (r = -0.7030) (p < 0.005). There is therefore wide variability in phenylalanine concentrations in a 24 hour period in children with phenylketonuria which is not reflected in a single observation. Further study is needed to investigate the effects of timing of protein substitute on the stability of phenylalanine concentrations.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9579152      PMCID: PMC1717471          DOI: 10.1136/adc.78.2.122

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  10 in total

1.  Preliminary neuropsychological test results.

Authors:  L M de Sonneville; E Schmidt; U Michel; U Batzler
Journal:  Eur J Pediatr       Date:  1990       Impact factor: 3.183

2.  Phenylketonuria: plasma phenylalanine responses to different distributions of the daily phenylalanine allowance over the day.

Authors:  F J van Spronsen; T van Dijk; G P Smit; M van Rijn; D J Reijngoud; R Berger; H S Heymans
Journal:  Pediatrics       Date:  1996-06       Impact factor: 7.124

3.  Amino acid metabolism after intense exercise.

Authors:  J T Devlin; I Brodsky; A Scrimgeour; S Fuller; D M Bier
Journal:  Am J Physiol       Date:  1990-02

4.  Plasma free amino acid values in normal children and adolescents.

Authors:  D M Gregory; D Sovetts; C L Clow; C R Scriver
Journal:  Metabolism       Date:  1986-10       Impact factor: 8.694

Review 5.  Plasma amino acids: screening, quantitation, and interpretation.

Authors:  C R Scriver; P Lamm; C L Clow
Journal:  Am J Clin Nutr       Date:  1971-07       Impact factor: 7.045

6.  Factors affecting the variation in plasma phenylalanine in patients with phenylketonuria on diet.

Authors:  A MacDonald; G Rylance; S K Hall; D Asplin; I W Booth
Journal:  Arch Dis Child       Date:  1996-05       Impact factor: 3.791

7.  Impaired prenatal and postnatal growth in Dutch patients with phenylketonuria. The National PKU Steering Committee.

Authors:  P H Verkerk; F J van Spronsen; G P Smit; R C Sengers
Journal:  Arch Dis Child       Date:  1994-08       Impact factor: 3.791

8.  Plasma phenylalanine and tyrosine responses to different nutritional conditions (fasting/postprandial) in patients with phenylketonuria: effect of sample timing.

Authors:  F J van Spronsen; M van Rijn; T van Dijk; G P Smit; D J Reijngoud; R Berger; H S Heymans
Journal:  Pediatrics       Date:  1993-10       Impact factor: 7.124

9.  Biochemical and neuropsychological effects of elevated plasma phenylalanine in patients with treated phenylketonuria. A model for the study of phenylalanine and brain function in man.

Authors:  W Krause; M Halminski; L McDonald; P Dembure; R Salvo; D Freides; L Elsas
Journal:  J Clin Invest       Date:  1985-01       Impact factor: 14.808

10.  Normal plasma free amino acid values in adults: the influence of some common physiological variables.

Authors:  C R Scriver; D M Gregory; D Sovetts; G Tissenbaum
Journal:  Metabolism       Date:  1985-09       Impact factor: 8.694

  10 in total
  17 in total

1.  Behavioural factors related to metabolic control in patients with phenylketonuria.

Authors:  M R Crone; F J van Spronsen; K Oudshoorn; J Bekhof; G van Rijn; P H Verkerk
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

Review 2.  The reality of dietary compliance in the management of phenylketonuria.

Authors:  Anita MacDonald; Hulya Gokmen-Ozel; Margreet van Rijn; Peter Burgard
Journal:  J Inherit Metab Dis       Date:  2010-04-07       Impact factor: 4.982

3.  Maternal phenylketonuria: report from the United Kingdom Registry 1978-97.

Authors:  P J Lee; D Ridout; J H Walter; F Cockburn
Journal:  Arch Dis Child       Date:  2005-02       Impact factor: 3.791

4.  The spectrum of phenylalanine variations under tetrahydrobiopterin load in subjects affected by phenylalanine hydroxylase deficiency.

Authors:  V Leuzzi; C Carducci; C Carducci; F Chiarotti; C Artiola; T Giovanniello; I Antonozzi
Journal:  J Inherit Metab Dis       Date:  2006-02       Impact factor: 4.982

5.  What Is the Best Blood Sampling Time for Metabolic Control of Phenylalanine and Tyrosine Concentrations in Tyrosinemia Type 1 Patients?

Authors:  Esther van Dam; Anne Daly; Gineke Venema-Liefaard; Margreet van Rijn; Terry G J Derks; Patrick J McKiernan; M Rebecca Heiner-Fokkema; Anita MacDonald; Francjan J van Spronsen
Journal:  JIMD Rep       Date:  2017-01-25

Review 6.  Protein substitutes for PKU: what's new?

Authors:  A Macdonald; A Daly; P Davies; D Asplin; S K Hall; G Rylance; A Chakrapani
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

7.  Preclinical evaluation of multiple species of PEGylated recombinant phenylalanine ammonia lyase for the treatment of phenylketonuria.

Authors:  Christineh N Sarkissian; Alejandra Gámez; Lin Wang; Marilyse Charbonneau; Paul Fitzpatrick; Jeffrey F Lemontt; Bin Zhao; Michael Vellard; Sean M Bell; Carroll Henschell; Amy Lambert; Laurie Tsuruda; Raymond C Stevens; Charles R Scriver
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-18       Impact factor: 11.205

8.  Protein substitute dosage in PKU: how much do young patients need?

Authors:  A MacDonald; A Chakrapani; C Hendriksz; A Daly; P Davies; D Asplin; K Hall; I W Booth
Journal:  Arch Dis Child       Date:  2006-03-17       Impact factor: 3.791

9.  A different approach to breast-feeding of the infant with phenylketonuria.

Authors:  Margreet van Rijn; Jolita Bekhof; Tietie Dijkstra; Peter G P A Smit; Pim Moddermam; Francjan J van Spronsen
Journal:  Eur J Pediatr       Date:  2003-03-04       Impact factor: 3.183

10.  Are tablets a practical source of protein substitute in phenylketonuria?

Authors:  A MacDonald; C Ferguson; G Rylance; A A M Morris; D Asplin; S K Hall; I W Booth
Journal:  Arch Dis Child       Date:  2003-04       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.